Commonwealth Equity Services’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$12.5M Buy
260,565
+9,996
+4% +$429K 0.02% 828
2026
Q1
$9.21M Buy
250,569
+19,109
+8% +$905K 0.01% 927
2025
Q4
$11.8M Sell
231,460
-6,518
-3% -$333K 0.02% 813
2025
Q3
$13.2M Sell
237,978
-237,049
-50% -$13.9M 0.02% 763
2025
Q2
$32.8M Buy
475,027
+95,756
+25% +$6.51M 0.04% 412
2025
Q1
$26.3M Sell
379,271
-29,565
-7% -$2.44M 0.04% 454
2024
Q4
$35.2M Sell
408,836
-20,497
-5% -$2.22M 0.05% 343
2024
Q3
$51.1M Sell
429,333
-76,659
-15% -$10.2M 0.08% 237
2024
Q2
$72.2M Buy
505,992
+97,209
+24% +$12.9M 0.11% 163
2024
Q1
$52.5M Buy
408,783
+172,206
+73% +$20.5M 0.09% 219
2023
Q4
$24.5M Buy
236,577
+40,524
+21% +$4.01M 0.04% 395
2023
Q3
$17.8M Buy
196,053
+6,965
+4% +$614K 0.04% 452
2023
Q2
$15.3M Buy
189,088
+25,418
+16% +$2.08M 0.03% 509
2023
Q1
$13K Buy
163,670
+8,612
+6% +$611K 0.03% 555
2022
Q4
$10.5M Sell
155,058
-1,112
-0.7% -$65.2K 0.03% 610
2022
Q3
$7.78M Buy
156,170
+1,024
+0.7% +$54.9K 0.02% 684
2022
Q2
$8.64M Sell
155,146
-17,256
-10% -$958K 0.02% 639
2022
Q1
$9.57M Sell
172,402
-2,266
-1% -$116K 0.02% 642
2021
Q4
$9.78M Sell
174,668
-4,392
-2% -$238K 0.02% 608
2021
Q3
$8.6M Sell
179,060
-3,494
-2% -$169K 0.02% 619
2021
Q2
$7.65M Buy
182,554
+1,572
+0.9% +$60.9K 0.02% 662
2021
Q1
$6.1M Buy
180,982
+11,036
+6% +$393K 0.02% 687
2020
Q4
$5.93M Buy
169,946
+11,200
+7% +$387K 0.02% 658
2020
Q3
$5.51M Buy
158,746
+2,528
+2% +$84.3K 0.02% 619
2020
Q2
$5.11M Buy
156,218
+1,884
+1% +$60.1K 0.02% 599
2020
Q1
$4.64M Sell
154,334
-9,720
-6% -$289K 0.02% 577
2019
Q4
$4.75M Buy
164,054
+18,948
+13% +$525K 0.02% 652
2019
Q3
$3.75M Sell
145,106
-5,982
-4% -$151K 0.02% 681
2019
Q2
$3.85M Sell
151,088
-53,094
-26% -$1.31M 0.02% 663
2019
Q1
$5.34M Buy
204,182
+7,246
+4% +$178K 0.02% 533
2018
Q4
$4.54M Buy
196,936
+6,928
+4% +$154K 0.02% 523
2018
Q3
$4.48M Sell
190,008
-904
-0.5% -$22.1K 0.02% 575
2018
Q2
$4.4M Sell
190,912
-2,072
-1% -$49.2K 0.02% 553
2018
Q1
$4.75M Sell
192,984
-286
-0.1% -$7.51K 0.03% 495
2017
Q4
$5.19M Sell
193,270
-10,166
-5% -$259K 0.03% 462
2017
Q3
$4.9M Sell
203,436
-1,622
-0.8% -$36.7K 0.03% 450
2017
Q2
$4.4M Buy
205,058
+38,464
+23% +$776K 0.03% 484
2017
Q1
$2.85M Buy
166,594
+7,596
+5% +$132K 0.02% 590
2016
Q4
$2.85M Buy
158,998
+33,742
+27% +$612K 0.02% 569
2016
Q3
$2.6M Buy
125,256
+6,294
+5% +$156K 0.02% 569
2016
Q2
$3.2M Sell
118,962
-4
-0% -$110 0.03% 491
2016
Q1
$3.22M Sell
118,966
-1,560
-1% -$41.8K 0.03% 472
2015
Q4
$3.5M Buy
120,526
+11,512
+11% +$319K 0.03% 436
2015
Q3
$2.96M Buy
109,014
+2,946
+3% +$83.4K 0.03% 463
2015
Q2
$2.9M Buy
106,068
+180
+0.2% +$5.06K 0.03% 489
2015
Q1
$2.83M Sell
105,888
-1,584
-1% -$36.5K 0.03% 496
2014
Q4
$2.27M Buy
107,472
+3,770
+4% +$84.2K 0.03% 525
2014
Q3
$2.47M Buy
103,702
+992
+1% +$22.8K 0.03% 486
2014
Q2
$2.37M Buy
102,710
+10,944
+12% +$242K 0.03% 500
2014
Q1
$2.1M Buy
91,766
+1,076
+1% +$22.9K 0.03% 506
2013
Q4
$1.68M Buy
90,690
+1,650
+2% +$28.8K 0.02% 557
2013
Q3
$1.51M Buy
89,040
+5,350
+6% +$90K 0.02% 548
2013
Q2
$1.3M Buy
+83,690
New +$1.39M 0.02% 565

Other funds holding NVO

Commonwealth Equity Services's NVO Position: Q2 2026 in Review

Commonwealth Equity Services increased its Novo Nordisk (NVO) stake by 4% in Q2 2026, buying an estimated $429K and bringing the position to 260,565 shares worth $12.5M. The position accounts for 0.02% of the portfolio, ranked #828.

Commonwealth Equity Services first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $72.2M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Commonwealth Equity Services held 260,565 shares of Novo Nordisk worth $12.5M as of Q2 2026.
  • Commonwealth Equity Services bought 9,996 Novo Nordisk shares in Q2 2026, an estimated $429K.
  • Novo Nordisk made up 0.02% of Commonwealth Equity Services's portfolio in Q2 2026, its #828 holding.
  • Commonwealth Equity Services first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Commonwealth Equity Services's Novo Nordisk position peaked at $72.2M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.